Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
Open Access
- 20 January 2018
- journal article
- review article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (9) , 8706-8715
Abstract
Analysis of response rate with ANTI-PD1/PDL-1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials Analysis of response rate with ANTI-PD1/PDL-1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trialsKeywords
This publication has 36 references indexed in Scilit:
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional MeasurementsClinical Cancer Research, 2013
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?Clinical Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986